



ASX ANNOUNCEMENT

30 June 2023

CardieX \$2.3m Convertible Note Facility and Dual Listing Update

[CardieX Limited](#) (ASX: **CDX**) (**CardieX**, the **Company**) is pleased to announce an update with respect to its Australian capital raising and US dual listing initiatives.

Convertible Note Facility – Capital Raising

Subscriptions Received

The Company is pleased to note that it is in receipt of subscriptions totaling \$2.30 million, to a Convertible Note Facility that the Company has established.

Of the funds subscribed to date of \$2.3m, \$1.5m has been received in Convertible Note subscriptions, and \$0.8m has been received in Converting Note subscriptions.

The total subscription proceeds received to date (\$2.175m) represent a material capital injection, which in addition to other operational receipts from our core business (cash inflows from clinical trial services, research and clinician sales) since our last quarterly activities report, provide a supportive addition to the Company's available working capital.

Subscriptions to date have been supported by Directors Mr Niall Cairns and Craig Cooper (through C2 Ventures Pty Limited), and Mr Jarrod White.

Key Terms of Convertible Note Facility

Subscription funds have been received under the Convertible Note Facility, from sophisticated investors and Directors for both Convertible Notes and Converting Notes, which have the following key terms:

- Coupon: 10% interest rate, paid quarterly.
- Conversion (subject to shareholder approval):
 - Convertible Notes convert at the holder's option;
 - Converting Notes convert at the Company's option, at the next capital raising (Australia or another jurisdiction) of A\$5,000,000 or more.

Either type of Note may be converted at the holder's option any time from the date 6 months after issue until the applicable Maturity Date.

- Conversion Pricing:
 - the higher of the Floor Price (being the lower of \$0.30 and the price of any capital raising prior to conversion); and
 - a 20% discount to the 20 day VWAP at conversion. For example, if the 20 day VWAP at conversion is above A\$0.36 then the conversion price will be a 20% discount to that higher price.



Option Coverage (subject to shareholder approval):

- Convertible Notes: 1 option (exercise price of \$0.45) for every \$2 invested.
- Converting Notes: 2 options (exercise price of \$0.45) for every \$1 invested.
- Maturity Date:
 - Convertible Notes: 15 July 2024 (unless the holder elects to extend maturity on the same terms as the Converting Notes).
 - Converting Notes: 15 July 2025. The holder may also elect to redeem these Notes at any time after 15 January 2025.

Further details of the terms of the Notes will be announced to ASX when the Notes are issued to subscribers in the near future.

The conversion feature of all of the Notes, as well as the issue of the options, will be put forward to shareholders at an upcoming shareholder meeting. Pending this shareholder approval the Notes will otherwise remain repayable by the Company at the applicable redemption or Maturity Date.

Dual Listing Update

We have continued to mindfully manage the Company's capital whilst being engaged in a significant process for a proposed dual/secondary listing of our shares on a US Exchange. This has required a material allocation of both senior management time and Company working capital.

The Board firmly believes a dual listing is the best strategy for the Company given the strategic opportunities, comparable valuations, and higher multiples applied to MedTech companies in the USA in the health technology sectors we are targeting.

Commercially the United States is the primary market focus for our ATCOR and CONNEQT products and we need to develop a stronger public presence with investors, partners, and our customers in that market.

The timing for a potential US Listing had been originally targeted for the period immediately following FDA clearance on the CONNEQT Pulse (Pulse) which was received on 26 April this year.

We continue to prioritise this initiative as an essential component of our overall corporate strategy in parallel to the overarching need of progressing the resourcing of operational, manufacturing, marketing and staffing requirements to ensure we commercially launch the Pulse as soon as possible.

As previously advised, there will be a need for the Company to convene a meeting of shareholders seeking approval for any capital raise associated with the US dual Listing. This will likely be circulated to shareholders over the course of July as the Company nears the appropriate timing in seeking the required shareholder approvals.

At the current stage our US counsel advise that there is no more that the Company can disclose.

Craig Cooper
Chief Executive Officer



Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CardieX

CardieX is a global medical technology company focused on developing and marketing products and solutions for vascular health. Its ATCOR subsidiary is a world leader in medical devices and arterial biomarkers for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's "gold standard" SphygmoCor® central blood pressure technology. CardieX's CONNEQT subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).